Olopatadine 0.2% provides extended efficacy during peak pollen periods

August 15, 2004

Fort Lauderdale, FL-A new formulation of an anti-allergy medication, olopatadine HCl ophthalmic solution 0.2% (Patanol II, Alcon Laboratories), provides two important advantages. It allows once-daily dosing, which increases patient compliance, and maintains the level of effectiveness of the original formulation, olopatadine 0.1%, during peak pollen seasons for an extended period up to 24 hours, according to Jack Greiner, DO, PhD.